Jeffrey Hoch : Citation Profile


Are you Jeffrey Hoch?

University of California-Davis

4

H index

2

i10 index

125

Citations

RESEARCH PRODUCTION:

18

Articles

4

Chapters

RESEARCH ACTIVITY:

   19 years (2002 - 2021). See details.
   Cites by year: 6
   Journals where Jeffrey Hoch has often published
   Relations with other researchers
   Recent citing documents: 1.    Total self citations: 6 (4.58 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pho785
   Updated: 2024-04-18    RAS profile: 2023-05-13    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Authors registered in RePEc who have co-authored more than one work in the last five years with Jeffrey Hoch.

Is cited by:

Rice, Nigel (6)

Sculpher, Mark (4)

Jones, Andrew (3)

Shih, Ya-Chen (3)

Svensson, Mikael (2)

Lomas, James (2)

Kreif, Noemi (2)

Gomes, Manuel (2)

Siciliani, Luigi (2)

EPSTEIN, DAVID (1)

Frew, Emma (1)

Cites to:

Johannesson, Magnus (4)

Rice, Nigel (3)

Devlin, Nancy (3)

Fenn, Paul (3)

Sculpher, Mark (3)

Mullahy, John (3)

Parkin, David (2)

Brazier, John (2)

Husereau, Don (2)

Kreif, Noemi (2)

Claxton, Karl (1)

Main data


Where Jeffrey Hoch has published?


Journals with more than one article published# docs
PharmacoEconomics6
PharmacoEconomics - Open4
PLOS ONE2
Health Economics2

Recent works citing Jeffrey Hoch (2024 and 2023)


YearTitle of citing document
2023Factors Facilitating or Creating Barriers to Returning to Work in Head and Neck Cancer Patients Within the First 6 Months After Treatment. (2023). Chang, Ya-Lan ; Cho, Kuei-An ; Chiu, Su-Erh ; Chung, Ching-Fang ; Lin, Chien-Yu ; Chen, Shu-Ching ; Huang, Bing-Shen. In: Clinical Nursing Research. RePEc:sae:clnure:v:32:y:2023:i:1:p:197-208.

Full description at Econpapers || Download paper

Works by Jeffrey Hoch:


YearTitleTypeCited
2008Measuring and illustrating statistical evidence in a cost-effectiveness analysis In: Journal of Health Economics.
[Full Text][Citation analysis]
article3
2014Public engagement in priority-setting: Results from a pan-Canadian survey of decision-makers in cancer control In: Social Science & Medicine.
[Full Text][Citation analysis]
article1
2021Labs and cases in health insurance and cost-effectiveness analyses to enhance active learning experiences in an introductory healtheconomics course for students in health professions In: Chapters.
[Full Text][Citation analysis]
chapter0
2021Using net benefit regression to teach cost-effectiveness analysis with a dataset In: Chapters.
[Full Text][Citation analysis]
chapter0
In: .
[Full Text][Citation analysis]
chapter0
2016Advice about Work-Related Issues to Peers and Employers from Head and Neck Cancer Survivors In: PLOS ONE.
[Full Text][Citation analysis]
article1
2017Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening In: PLOS ONE.
[Full Text][Citation analysis]
article1
2014A Review and Meta-analysis of Colorectal Cancer Utilities In: Medical Decision Making.
[Full Text][Citation analysis]
article4
2016Using Phase-Based Costing of Real-World Data to Inform Decision–Analytic Models for Atrial Fibrillation In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]
article0
2013Improving the Efficiency of Cost-effectiveness Analysis to Inform Policy Decisions in the Real World: Lessons from the Pharmacoeconomics Research Unit at Cancer Care Ontario In: International Series in Operations Research & Management Science.
[Citation analysis]
chapter0
2007Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions In: PharmacoEconomics.
[Full Text][Citation analysis]
article2
2013The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada In: PharmacoEconomics.
[Full Text][Citation analysis]
article5
2015Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters In: PharmacoEconomics.
[Full Text][Citation analysis]
article1
2015Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale? In: PharmacoEconomics.
[Full Text][Citation analysis]
article0
2018Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment In: PharmacoEconomics.
[Full Text][Citation analysis]
article0
2019A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost?Effectiveness Analysis In: PharmacoEconomics.
[Full Text][Citation analysis]
article0
2017Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology In: PharmacoEconomics - Open.
[Full Text][Citation analysis]
article0
2017Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR) In: PharmacoEconomics - Open.
[Full Text][Citation analysis]
article0
2018The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study In: PharmacoEconomics - Open.
[Full Text][Citation analysis]
article0
2018Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom In: PharmacoEconomics - Open.
[Full Text][Citation analysis]
article0
2002Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost?effectiveness analysis In: Health Economics.
[Full Text][Citation analysis]
article70
2004Regression methods for covariate adjustment and subgroup analysis for non?censored cost?effectiveness data In: Health Economics.
[Full Text][Citation analysis]
article37

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated March, 4 2024. Contact: CitEc Team